This trial is active not recruiting!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
2Find
3Review
4Get in touch
More info
You can access this
clinical trial
if you have
Lymphoblastic Lymphoma
and you are
under 21
years old
2
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

This is a phase II clinical trial using risk-adapted therapy. The treatment is acute lymphoblastic leukemia (ALL)-based therapy, using multi-agent regimens comprising of induction, consolidation, and continuation (maintenance) phases delivered over 24-30 months. Participants will be classified into 3 treatment stratums, based on bone marrow/peripheral blood lymphoma cells involvement at diagnosis and day 8 for T-lymphoblastic lymphoma and bone marrow/peripheral blood lymphoma cells involvement at diagnosis for B-lymphoblastic lymphoma. The Primary Objective of this study is: To improve the outcome of children with lymphoblastic lymphoma (LL) who have minimal disseminated disease (MDD) equal to or more than 1% at diagnosis by using MDD- and minimal residual disease (MRD)- based risk-adapted therapy. The Secondary Objectives of this study are: - To estimate the event-free survival and overall survival of children with lymphoblastic lymphoma who are treated with MDD- or MRD-based risk- directed therapy. - To evaluate the prognostic value of levels of MDD at diagnosis and MRD on day 8 of remission induction.

Provided treatments

  • Drug: Prednisone
  • Drug: Vincristine
  • Drug: Daunorubicin
  • Drug: PEG-asparaginase
  • Drug: Erwinia asparaginase
  • Drug: Doxorubicin
  • Drug: Cyclophosphamide
  • Drug: Cytarabine
  • Drug: Thioguanine
  • Drug: Clofarabine
  • Drug: Methotrexate
  • Drug: Mercaptopurine
  • Drug: Dexamethasone
  • Drug: Hydrocortisone
  • Drug: Etoposide

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01451515. The sponsor of the trial is St. Jude Children's Research Hospital and it is looking for 23 volunteers for the current phase.
Official trial title:
NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma